pioglitazone has been researched along with rotenone in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Althaym, A; Brunmair, B; Clara, R; Fürnsinn, C; Gnaiger, E; Gras, F; Nohl, H; Roden, M; Scharf, N; Staniek, K; Waldhäusl, W | 1 |
Celik, T; Gürsoy, M; Isik, AT; Kayir, H; Ulusoy, GK; Uzbay, TI | 1 |
Bernardo, A; Cruciani, C; De Nuccio, C; De Simone, R; Minghetti, L; Visentin, S | 1 |
7 other study(ies) available for pioglitazone and rotenone
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
Topics: Animals; Electron Transport Complex I; Energy Metabolism; Hypoglycemic Agents; Male; Metformin; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Potassium Chloride; Rats; Rats, Sprague-Dawley; Rosiglitazone; Rotenone; Thiazolidinediones | 2004 |
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Pioglitazone; Rats; Rats, Wistar; Rotenone; Thiazolidinediones; Tretinoin | 2011 |
Peroxisome proliferator activated receptor-γ agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Bradykinin; Bradykinin Receptor Antagonists; Calcium; Cell Differentiation; Cyclooxygenase 1; Dose-Response Relationship, Drug; Ion Channels; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Oligodendroglia; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rotenone; Stem Cells; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha; Uncoupling Protein 2 | 2015 |